Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

ALKS 60.97 -1.55 (-2.48%)
price chart
Alkermes Plc Cut to Neutral at Citigroup Inc. (ALKS)
Alkermes Plc logo Citigroup Inc. cut shares of Alkermes Plc (NASDAQ:ALKS) from a buy rating to a neutral rating in a research note issued to investors on Friday, TheFlyOnTheWall.
Alkermes Plc Stock Rating Lowered by Citigroup Inc. (ALKS)  WKRB News
Alkermes 'Taking A Pause,' Citi Says  Benzinga
Alkermes Plc (ALKS) Downgraded From Hold to Sell
"We rate ALKERMES PLC (ALKS) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover.
Alkermes Plc Lowered to Sell at TheStreet (ALKS)  Dakota Financial News
Insider Selling: Alkermes Plc COO Sells $1070850.00 in Stock (ALKS)  The Legacy
Alkermes Plc To Sell Georgia Facility To Recro Pharma; Recro Shares Soar 35%
Alkermes Plc (NASDAQ:ALKS), a biopharmaceutical company focusing on central nervous system diseases, announced Monday its plans to divest its Gainesville, Georgia manufacturing facility.
Alkermes Plc Price Target Cut to $78.00 (ALKS)  sleekmoney
Alkermes plc (NASDAQ:ALKS) Signed Into A Definitive Contract To Sell Its ...  StreetWise Report
Alkermes Plc insider Shane Cooke Sells 18000 Shares (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) insider Shane Cooke sold 18,000 shares of the company's stock in a transaction that occurred on Monday, March 23rd.
The Insider and President - Alkermes plc of Alkermes Plc (NASDAQ:ALKS ...
Insider Selling: Alkermes Plc insider Sells $1175940.00 in Stock (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) insider Shane Cooke sold 18,000 shares of the stock in a transaction dated Monday, March 23rd.
Is Alkermes plc Stock Undervalued?
In simple terms, what Alkermes plc (NASDAQ: ALKS ) is attempting to do is not easy. Few companies manage to successfully transition from being a licensor of drug formulation technologies to a proprietary drug developer and likewise few independent ...
Alkermes plc (ALKS) is Trading Lower on Unusual Volume for March 20
Alkermes plc ($ALKS) experienced unusually high volume on Mar. 20, as the stock lost 1.26% to a closing price of $67.20. The stock saw 3.44 million shares trade hands over the course of the day on 11,048 trades.
Alkermes Plc Receives Consensus Recommendation of �Hold� from Brokerages ...
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) has received a consensus recommendation of �Hold� from the ten brokerages that are currently covering the company, Analyst Ratings Net reports.
Alkermes plc (ALKS) Phase 1 Study of ALKS 7106 Fails, Further Development ...
Alkermes plc (NASDAQ: ALKS) today announced topline results from a phase 1 clinical study of ALKS 7106, a new molecule intended for the treatment of pain.
Citigroup Inc. Lowers Alkermes Plc Price Target to $83.00 (ALKS)  Dakota Financial News
Alkermes Plc (ALKS) Discontinues Development Of Pain Treatment; Stock Drops  Bidness ETC
Alkermes Plc Stock Rating Lowered by Morgan Stanley (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) was downgraded by Morgan Stanley from an �equal weight� rating to an �underweight� rating in a research note issued on Thursday, TheFlyOnTheWall.
Alkermes plc Short Interest Disclosure  Stafford Daily
Alkermes Plc CFO James M. Frates Sells 10000 Shares (ALKS)  The Legacy